Charles River Laboratories International, Inc. Class Action Lawsuit - CRL
Investors who suffered a loss and would like to learn more, click here to contact us.
The Charles River Laboratories class action lawsuit seeks to represent purchasers or acquirers of Charles River Laboratories International, Inc. (NYSE: CRL) securities between May 5, 2020 and February 21, 2023, inclusive (the “Class Period”). Captioned Coleman v. Charles River Laboratories International, Inc., No. 23-cv-11132 (D. Mass.), the Charles River Laboratories class action lawsuit charges Charles River Laboratories and several of its current and former top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Charles River Laboratories class action lawsuit, please provide your information in the form on this page. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at email@example.com. Lead plaintiff motions for the Charles River Laboratories class action lawsuit must be filed with the court no later than July 18, 2023.
CASE ALLEGATIONS: Charles River Laboratories is a pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the pharmaceutical, medical device, and biotechnology industries.
The Charles River Laboratories class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Charles River Laboratories had engaged in illegal activity with respect to its importation of non-human primates for research; (ii) as a result, Charles River Laboratories was at a heightened risk of criminal and regulatory investigation by, among others, the U.S. Department of Justice (“DOJ”); and (iii) consequently, Charles River Laboratories would be forced to suspend shipments of primates from Cambodia.
On February 22, 2023, Charles River Laboratories revealed that it had received a subpoena from the DOJ relating to an ongoing investigation in conjunction with U.S. Fish and Wildlife Service into the supply chain and illegal importation of non-human primates for research. Charles River Laboratories noted that it was voluntarily suspending shipments of primates from Cambodia, which would negatively impact its earnings for the year and would reduce revenue growth by 200 to 400 basis points. On this news, the price of Charles River Laboratories stock declined more than 10%, damaging investors.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Charles River Laboratories securities during the Class Period to seek appointment as lead plaintiff of the Charles River Laboratories class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Charles River Laboratories class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Charles River Laboratories class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Charles River Laboratories class action lawsuit.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: Robbins Geller Rudman & Dowd LLP is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report for recovering more than $1.75 billion for investors in 2022 – the third year in a row Robbins Geller tops the list. And in those three years alone, Robbins Geller recovered nearly $5.3 billion for investors, more than double the amount recovered by any other plaintiffs’ firm. With 200 lawyers in 9 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig.